|

Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] Clinical Trials

1 actively recruiting trial

Also known as: JEMPERLI

Pipeline

Phase 2: 1

Top Sponsors

  • Queensland Centre for Gynaecological Cancer1

Indications

  • Immune-related Adverse Event1
  • Endometrioid Endometrial Adenocarcinoma1
  • Mmr Deficiency1
  • Endometrial Cancer Stage I1
  • Cancer1

Other1 trial

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.